Vessel Harvesting Device Cleared by FDA

A bipolar device that simplifies the harvesting of the greater saphenous vein for coronary artery bypass surgery has been cleared by the U.S. Food and Drug Administration (FDA).

The device is a sterile, single-patient instrument that clamps, coagulates, and transects tissue with an integral knife blade. Patented offset electrode technology reduces the potential for injury to the vessel and surrounding tissue. The device is offered as part of the ClearGlide Accel Endoscopic Vessel Harvest (EVH) system, which also includes dissectors, a retractor, and scissors. This system allows doctors to identify and remove the saphenous vein through one to two incisions, about three to four inches in length, at the knee. Compared to the open approach, removing the vein through a small incision can lessen postoperative pain, reduce the risk of wound complications, and cause less scarring.

The Accel EVH system is the product of Cardiovations (Somerville, NJ, USA), a division of Ethicon, Inc.. The company notes that, as with any surgical procedure, there are risks associated with the EVH system. Possible complications include bleeding, infection, nerve damage, leg swelling, and damage to the saphenous vein.



Related Links:
Ethicon